Arrowhead Pharmaceuticals Advances First Dual-Gene RNAi Therapeutic into Clinical Trials

Event summary

  • Arrowhead Pharmaceuticals has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, an RNAi therapeutic targeting mixed hyperlipidemia.
  • ARO-DIMER-PA is designed to silence both PCSK9 and APOC3 genes simultaneously using Arrowhead’s TRiM™ platform.
  • The study (NCT07223658) will evaluate safety, tolerability, pharmacokinetics, and effects on LDL-C and triglycerides in up to 78 subjects.
  • Arrowhead’s portfolio includes the approved REDEMPLO® for familial chylomicronemia syndrome and ongoing studies for obesity treatments.

The big picture

Arrowhead Pharmaceuticals is pushing the boundaries of RNAi therapeutics with ARO-DIMER-PA, the first clinical candidate to target two genes simultaneously. This innovation could address residual risk in patients with mixed hyperlipidemia, a prevalent disorder linked to atherosclerotic cardiovascular disease (ASCVD). The company’s growing focus on cardiometabolic diseases positions it as a key player in developing next-generation therapies for complex genetic disorders.

What we're watching

Therapeutic Efficacy
Whether ARO-DIMER-PA can demonstrate superior efficacy in reducing LDL-C and triglycerides compared to single-gene targeting therapies.
Regulatory Pathway
The pace at which Arrowhead can advance ARO-DIMER-PA through clinical trials given the novel dual-gene approach.
Market Differentiation
How Arrowhead positions ARO-DIMER-PA against existing and emerging treatments for mixed hyperlipidemia and ASCVD.